Charles de Giorgio Ltd., in collaboration with Eli Lilly, proudly announced the official launch of Mounjaro (tirzepatide) in Malta. The event marked a significant milestone in the management of type 2 diabetes, introducing an innovative treatment option that has transformed diabetes care globally.

The launch event, held in Malta, brought together leading healthcare professionals, endocrinologists, pharmacists, and representatives from the medical community. Attendees had the opportunity to learn more about the science behind Mounjaro and its dual GIP and GLP-1 receptor agonist action, which has been shown to improve glycaemic control and support weight reduction in adults with type 2 diabetes.

In his address, a representative from Charles de Giorgio Ltd. highlighted the company’s ongoing commitment to bringing world-class healthcare innovations to Malta. “We are proud to partner with Eli Lilly in introducing Mounjaro to the local market,” he said. “This launch reinforces our mission to enhance patient care and provide healthcare professionals with the most advanced treatment options available.”

With the introduction of Mounjaro, Malta joins several European countries offering this breakthrough therapy to patients living with type 2 diabetes. The medicine represents a new chapter in diabetes management, empowering patients and clinicians with an effective and innovative solution.